Use of miRNAs in Growth Hormone Deficiency (GHD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-13

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

miRNA as a Growth Plate Marker After GH

NCT05946915

MicroRNAs: D13.444.735.790.552.500

UNKNOWN

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients

NCT01822340

Adult Growth Hormone Deficiency

COMPLETED PHASE2

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

NCT02558829

Growth Hormone Deficiency With Pituitary Anomalies

COMPLETED PHASE3

Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle

NCT03878992

Growth Hormone Deficiency Growth Hormone Treatment

UNKNOWN NA

Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency

NCT00646815

Growth Hormone Deficiency

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 200 prepubertal and pubertal subjects with the suspicion of GHD, the levels of three specific circulating miRNas will be measured to establish whether they can be used for the diagnosis of GH deficiency. In subjects with isolated idiopathic GHD (IIGHD), short statured patients born SGA, Noonan and Turner syndromes, and SHOX deficiency, we will also assess the changes of the identified miRNAs before and after 3 months on GH therapy to verify an early growth prediction model for growth response at 12 months on treatment. Finally, we plan to identify any differences in these miRNAs at 3 months on treatment using daily GH versus weekly (long-acting) GH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Hormone Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children with short stature and suspicion of GHD
* Subjects with organic GH deficiency

* patients having confirmed GHD enrolled for aim 1
* patients with growth failure and born SGA (\>4 yr of age)
* patients with Noonan and Turner syndrome and growth failure
* patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure

\- Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy